Protagonist Therapeutics Inc Stock News

Protagonist has recently faced a number of mishaps. These make the stock risky.

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on

Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.

Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced

Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943 Protagonist Therapeutics

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-se

Shares of Protagonist Therapeutics Inc. PTGX, -0.58% tumbled 30.8% in premarket trading on Tuesday the day after the company said a Phase 2 clinical trial that gave patients a higher dose of its exper

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11 Pfizer Inc (

Protagonist Therapeutics Inc (NASDAQ: PTGX) received a letter from the FDA indicating the agency's intent to rescind Breakthrough Therapy Designation for the company's rusfertide product candidate

Protagonist Therapeutics (NASDAQ: PTGX ) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc , a unit of Johnson & Johnson (NYSE: JNJ ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b … Full story available on Benzinga.com